Shots:

• Takeda has submitted an NDA to MHLW to import and distribute Moderna’s (mRNA-1273/ TAK-919) in Japan
• Takeda is conducting a P- I/II study assessing the safety and immunogenicity of two vaccinations of TAK-919 (100μg- given 28 days apart) in 200 participants aged ≥20yrs. followed through 12mos. after the second vaccination. Takeda has completed enrollment in the P-I/II study of TAK-919 in Feb’2021
• Takeda will import and distribute 50M doses of Moderna’s COVID-19 vaccine candidate in H1’21- following the pending licensure in Japan

 ­ Ref: Moderna | Image:Takeda